Akın KAYA, Uğur GÖNÜLLÜ, Elif ŞEN, Serhat EROL, İsmail SAVAŞ

Kadınlarda akciğer kanseri: Klinik özellikler ve sağkalıma etkili faktörler

Dünya genelinde kadınlarda akciğer kanseri artmaktadır. Sigara içen kadınlarda akciğer kanseri gelişimine yatkınlıktaki farklarla başlayan süreç, hastalık seyrinde de erkeklerden farklar gösterebilmektedir. Bu çalışmada Ocak 2000 – Aralık 2005 tarihleri arasında akciğer kanseri tanısı alan akciğer kanserli kadın hastalarımızın klinik özellikleri, sağkalıma etkili faktörlerin değerlendirilmesi amaçlandı. Yüz dokuz kadın hastanın verileri değerlendirildi. Hastaların yaş ortalamaları 59.40±11,56’ydi ve 17’si (%15.6) sigara içiyordu. Ailesinde kanser öyküsü olan 20 hastanın (%18,3), %55’inin ailesinde akciğer kanseri vardı. Başvuruda öksürük (%81.7), nefes darlığı(%78.9), göğüs ağrısı (%40.3) en sık görülen semptomlardı. Bronkoskopik olarak tümör yerleşiminin en sık sağ üst lobda (%16,5) olduğu belirlendi. Tüm grupta histopatolojik tanıların dağılımı sırasıyla; adenokanser (%44.9), KHAK (%19.3), tiplendirilemeyen KHDAK (%22.0), yassı hücreli (%10.1), karsinoid tümör (%2.8) olarak belirlendi, sigara içmeyen hastalarda adenokarsinomanın sigara içenlerle karşılaştırıldığında anlamlı olarak daha fazla olduğu (%44.9/%17.7) görüldü (p

Lung cancer in women: Clinical features and factors related to survival

Lung cancer in women is increasing in worldwide. This process beginning with the difference on the susceptibility of lung cancer in women smokers may be different from men in the prognosis. In this study, it was aimed to evaluate the clinical features, and prognostic factors of female patients with lung cancer diagnosed between January 2000 - December 2005. The data of 109 patieints data was evaluated. The mean age was 59,40 ± 11,56 and 17 patients (%15,6) were smokers. In 20 patients(18,3%) having a family history of cancer, 55% of them had a relative with lung cancer. In admission, cough (81,7%), dyspnea (78,9%), chest pain (40,3%) were the most frequent presenting symptoms. The most common site of tumoral lesion in bronchoscopy were right upper lobe (16,5%). In the study group histopathological diagnosis were as follows; adenocarcinoma (%44.9), small cell lung cancer 19,3%, squamous cell (10.1%), non-small cell lung cancer --undefined (22.0%), carsinoid tumors (2,8%), in non-smokers adenocarcinoma was significantly higher than smokers (44.9%/17.7%) (p

PDF

___

1. Belani CP, Marts S, Schiller J, Socinski MA. Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 2007; 55:15-23.
2. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. Cancer J Clin 2007; 57: 43-66.
3. İtil O. Akciğer kanserlerinin epidemiyolojisi ve etyolojisi. Haydaroğlu A (editör). Akciğer Kanserleri: Tanı ve Tedavi. İzmir: Ege Üniversitesi Basımevi, 2000: 15-34.
4. The Ministry of Health Department of Cancer Control. Cancer Control Programme and Cancer Statistics in Turkey (1995-1999). Ankara 2002: 135-61.
5. Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994: First results from Izmir Cancer Registry. Eur J Cancer 2001; 37: 83-92.
6. Goksel T, Akkoclu A; Turkish Thoracic Society, Lung and Pleural Malignancies Study Group. Pattern of lung cancer in Turkey, 1994-1998. Respiration 2002; 69: 207-10.
7. Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers? A case- control analisys by histological type. Am J Epidemiol 1993; 138: 281-93.
8. Bain C, Feskanich D, Speizer F, et al. Lung cancer rates in men and women comparable histories of smoking. J Natl Cancer Inst 2004; 96: 826-34.
9. Novello S, Baldini E. Women and lung cancer. Ann Oncol 2006; 17(Supp 2): 79-82.
10. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002; 13: 1087-93.
11. Patel JD, Bach PB, Kris MG. Lung cancer in US women, a contemporary epidemic. JAMA 2004; 291: 1763-8.
12. Thomas L, Doyle A, Edelman MJ. Lung cancer in women, emerging differences in epidemiology, biology and therapy. Chest 2005; 128: 370-81.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982; 5: 649-55.
14. World Health Organization. Histological typing of lung and pleural tumors. World Health Organization, Copenhagen, 1999.
15. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
16. Fu JB, Ying Kau T, Severson RK, Kalemkerian GP. Lung cancer in women, analysis of the national surveillance, epidemiology, and end results database. Chest 2005;127: 768-77.
17. Utkaner G, Yılmaz U, Çelikten E, Gürsoy M. Primer akciğer kanserli 116 kadın olgunun analizi. Solunum Hastalıkları 1996; 7: 1-9.
18. Yurdakul A, Çalışır H, Demirağ F ve ark. Akciğer kanserinin histolojik tiplerinin dağılımı. Toraks Dergisi 2002; 3:59-65.
19. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: Epidemiology, prevention, and early detection. Lancet Oncology 2003; 4: 45-55.
20. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: Examination of the evidence. J Natl Cancer Inst 1996; 88: 183-92.
21. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997; 315: 980-8.
22. Fontham ET, Correa P, Reynolds P, et al. Environmental tobacco smoke and lung cancer in nonsmoking women: A multicenter study. JAMA 1994; 271: 1752-9.
23. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144: 554-62.
24. Wu AF, Fontham ET, Reynolds P, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996;143: 535-42.
25. Alavanja MCR, Browson RC, Boice JD, Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 1992; 136: 623-32.
26. Blanchon F, Grivaux M, Collon T, et al. Epidemiologic of primary bronchial carcinoma management in the general French hospital centers. Rev Mal Respir 2002; 19: 727-34.
27. Charcioux A, Rossignol M, Purohit A, et al. International differences in epidemiology of lung adenocarcinoma. Lung Cancer 1997; 16: 133-43.
28. Muscat JE, Wynder EL. Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett 1995;88: 1-5.
29. Stellman SD, Muscat JE, Thompson S, et al. Risk of squamous cell carcinoma and adenocarcinoma of lung in relation to lifetime filter cigarette smoking. Cancer 1997;80: 382-8.
30. Köktürk N, Yeğin D, Çiftçi Ulukavak T ve ark. Akciğer kanserlerinde epidemiyolojik özellikler yıllar içinde değişim gösteriyor mu? Toraks Dergisi 2004; 5: 137-42.
31. Bozkurt B, Selçuk ZT, Fırat P ve ark. 1972-2005 döneminde Hacettepe Üniversitesi Tıp Fakültesi Hastanesi’nde akciğer kanseri tanısı konulan hastaların histolojik ve epidemiyolojik değerlendirmesi. Toraks Dergisi 2004; 5:148-53.
32. Çelikoğlu SI, Aykan TB, Karyel T. Bronchoscopic findings: Review of 345 cases. Respiration 1986; 49: 132-6.
33. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006; 1: 441-6.
34. Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 2005; 23: 850-6.
35. Johnson BE, Steinberg SM, Phelps R, et al. Female patients with small cell lung cancer live longer than male patients. Am J Med 1988; 85: 194-6.
36. Ginsberg RJ, Vokes EE, Rosenweig K. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer Principles and Practice of Oncology. 6th ed. Lippincott Williams and Wilkins, 2001: 925-83.
37. Siegel Lakhai WS, Beijenen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005; 10: 579-89.
38. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non small cell lung cancer: Molecular analysis of IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-92.